Promis Competitors

Stocks . Germany . 
Stock . Promis Neurosciences
23J Stock  EUR 13.40  0.20  1.47%   
Promis Neurosciences competes with AUREA SA, Superior Plus, Intel, Volkswagen, and Bitwise Core; as well as few others. The company classifies itself under Biotechnology sector and is part of Health Care industry. Analyzing Promis Neurosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Promis Neurosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Promis Neurosciences Correlation with its peers.
For more detail on how to invest in Promis Stock please use our How to Invest in Promis Neurosciences guide.

Promis Neurosciences vs Toyota Tsusho Correlation

Modest diversification

The correlation between Promis Neurosciences and 9TO is 0.2 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Promis Neurosciences and 9TO in the same portfolio, assuming nothing else is changed.

Moving against Promis Stock

  0.46WAC Wacker Neuson SEPairCorr
  0.4HHX HAMMONIA SchiffsholdingPairCorr
  0.39W060 Byggmästare Anders SplitPairCorr
  0.36MUM Mensch und MaschinePairCorr
Hype
Prediction
LowEstimatedHigh
7.2813.5019.72
Details
Intrinsic
Valuation
LowRealHigh
3.489.7015.92
Details
Naive
Forecast
LowNextHigh
9.7615.9922.21
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3.857.5911.33
Details

Promis Neurosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Promis Neurosciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Promis and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Promis Neurosciences does not affect the price movement of the other competitor.

High positive correlations

9TO
+ 0.88
RS6
RS6
+ 0.84
INL
9TO
+ 0.82
RRU
RS6
+ 0.79
RRU
9TO
+ 0.78
INL
RRU
+ 0.74
INL
  

High negative correlations

RS6
- 0.56
BTC1
BTC1
- 0.55
VOW
3RKU
- 0.53
VOW
9TO
- 0.5
BTC1
9K1
- 0.44
BTC1
VOW
- 0.44
8SP

Risk-Adjusted Indicators

There is a big difference between Promis Stock performing well and Promis Neurosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Promis Neurosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
94P  1.91  0.02 (0.02) 1.25  2.39 
(1.99)
 3.44 
(3.93)
 11.80 
8SP  1.37 (0.17) 0.00 (0.27) 0.00 
 0.00 
 2.29 
(2.27)
 21.96 
INL  3.25  0.28  0.06  0.29  4.20 
(3.27)
 8.76 
(5.60)
 24.14 
VOW  0.78  0.18  0.06 (3.36) 0.80 
(1.21)
 2.12 
(1.53)
 6.95 
BTC1  2.29 (0.75) 0.00 (0.97) 0.00 
 0.00 
 3.90 
(5.63)
 14.40 
RRU  1.91  0.10  0.01  0.59  2.29 
(1.93)
 3.53 
(3.36)
 9.23 
RS6  1.16  0.27  0.20  0.71  0.80 
(1.41)
 3.18 
(1.57)
 5.54 
9K1  1.39  0.13  0.01 (0.17) 1.61 
(1.93)
 3.05 
(2.79)
 12.62 
3RKU  2.36  0.07  0.03  0.15  2.60 
(2.95)
 5.45 
(4.49)
 15.14 
9TO  1.96  0.44  0.15 (36.73) 1.90 
(2.54)
 4.23 
(2.82)
 13.02 

Promis Neurosciences Competitive Analysis

The better you understand Promis Neurosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Promis Neurosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Promis Neurosciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
23J 94P 8SP INL VOW BTC1 RRU RS6 9K1 3RKU
 1.47 
 13.40 
Promis
 2.45 
 5.86 
AUREA
 2.27 
 4.30 
Superior
 3.74 
 43.00 
Intel
 0.00 
 104.80 
Volkswagen
 1.91 
 5.87 
Bitwise
 1.71 
 14.24 
Rolls-Royce
 3.60 
 293.20 
Reliance
 2.79 
 1.74 
NORDIC
 4.37 
 8.35 
RYOHIN
Market Volatility
(90 Days Market Risk)
Slightly risky
Slightly risky
Moderately volatile
Not too volatile
Very steady
Slightly risky
Not too volatile
Very steady
Risky
Slightly risky
Market Performance
(90 Days Performance)
Good
Soft
Weakest
Fair
Fair
Weakest
Soft
Solid
Fair
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
High
High
Low
Low
Tiny
Low
Tiny
Low
Fair
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Buy
Strong Sell
Strong Sell
Current Ratio
19.07
N/A
1.33
N/A
N/A
N/A
1.07
4.06
N/A
4.01
Net Asset
18.91 M
N/A
3.69 B
211.43 B
632.9 B
N/A
35.69 B
10.02 B
N/A
N/A
Profit Margin
N/A
-0.0077
0.0064
N/A
N/A
N/A
0.3
0.0523
N/A
0.0711
EBITDA
(14.02 M)
10.12 M
422.7 M
21.3 B
49.43 B
N/A
3.48 B
1.3 B
N/A
113.61 B
Current Valuation
16.09 M
70.61 M
2.53 B
211.96 B
177.29 B
N/A
114.31 B
16.38 B
114.14 M
9.13 B
Price To Book
3.76
0.73
1.39
2.14
0.29
N/A
41.66
2.48
1.64
4.28
Operating Margin
N/A
-0.0063
-0.16
N/A
N/A
N/A
0.19
0.0714
N/A
0.12
Retained Earnings
(90.69 M)
N/A
(1.73 B)
48.98 B
155.13 B
N/A
(4.41 B)
7.33 B
N/A
N/A
Five Year Return
N/A
N/A
5.75
N/A
N/A
N/A
N/A
1.9
N/A
N/A
One Year Return
N/A
N/A
N/A
N/A
N/A
-26.3
N/A
N/A
N/A
N/A
Beta
-0.093
0.55
0.43
N/A
N/A
N/A
1.15
0.9
N/A
0.52
Number Of Employees
7
570
N/A
N/A
N/A
N/A
42.4 K
15.9 K
N/A
13.91 K
Shares Outstanding
7.2 M
9.35 M
222.97 M
N/A
N/A
N/A
8.28 B
52.29 M
N/A
1.06 B
Cash Flow From Operations
(27.18 M)
N/A
274.1 M
9.7 B
17.15 B
N/A
3.78 B
1.43 B
N/A
(3.52 B)
Annual Yield
N/A
0.0262
0.0259
N/A
0.0688
N/A
0.0074
0.0141
N/A
0.009
Total Debt
2.42 M
N/A
7.2 M
2.5 B
62.13 B
N/A
801 M
399.7 M
N/A
110.72 B
Return On Equity
-3.56
-0.0293
0.0306
N/A
N/A
N/A
0.58
0.0996
N/A
0.17
Return On Asset
-0.85
0.0027
0.0347
N/A
N/A
N/A
0.0562
0.0614
N/A
0.0854
Book Value Per Share
3.62
7.81
3.1
N/A
N/A
N/A
0.33
118.42
N/A
3.75
Total Asset
18.91 M
N/A
3.69 B
211.43 B
632.9 B
N/A
35.69 B
10.02 B
N/A
N/A
Debt To Equity
0.66
N/A
163.2
N/A
N/A
N/A
580.9
49.0
N/A
0.52
Last Dividend Paid
N/A
0.15
0.1
0.33
4.8
N/A
0.11
4.7
N/A
25.0
Target Price
N/A
N/A
N/A
N/A
N/A
N/A
N/A
181.17
N/A
N/A
Shares Owned By Institutions
18.42
8.89
20.62
N/A
N/A
N/A
70.55
83.13
N/A
N/A
Market Capitalization
725.54 K
54.24 M
1.03 B
182.18 B
117.75 B
N/A
117.96 B
15.37 B
N/A
8.86 B
Price To Earning
N/A
N/A
30.24
N/A
N/A
N/A
5.69
8.86
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
0.5
0.83
N/A
2.71
N/A
N/A
N/A
Price To Sales
4159.1
0.25
0.42
4.19
0.16
N/A
6.04
1.1
7.57
0.0109
Net Income
2.78 M
N/A
(36.8 M)
(267 M)
11.35 B
N/A
2.52 B
875.2 M
N/A
(6.93 B)
Earnings Per Share
-16.95
-0.22
0.06
N/A
N/A
N/A
0.79
11.64
N/A
0.26
Shares Owned By Insiders
24.6
76.66
0.3
N/A
N/A
N/A
0.04
0.34
N/A
N/A
Revenue
N/A
221.09 M
2.38 B
52.85 B
324.65 B
N/A
18.91 B
13.84 B
N/A
815.17 B
Working Capital
16.69 M
N/A
(26.2 M)
32.11 B
28.19 B
N/A
4.86 B
2.68 B
N/A
N/A
Cash And Equivalents
21.5 M
N/A
33.45 M
N/A
N/A
N/A
5.81 B
133.6 M
N/A
126.74 B
Cash Per Share
0.05
N/A
0.19
N/A
N/A
N/A
3.14
1.99
N/A
481.84
Gross Profit
(28.34 M)
13.01 M
1.23 B
N/A
N/A
N/A
4.94 B
4.05 B
N/A
421.13 B
Day Typical Price
13.43
5.86
4.3
42.23
104.8
5.73
14.15
293.2
1.75
8.35
Accumulation Distribution
0.0074
N/A
N/A
1.39
N/A
21763.37
28.45
N/A
0.0114
N/A
Market Facilitation Index
0.1
N/A
N/A
0.0885
N/A
0.0
4.0E-4
N/A
0.02
N/A
Daily Balance Of Power
(2.00)
9.2 T
0
0.6739
0.0
0.2619
0.6
9.2 T
(2.50)
9.2 T
Period Momentum Indicator
(0.20)
0.14
(0.10)
1.55
N/A
0.11
0.24
10.2
(0.05)
0.35
Rate Of Daily Change
0.99
1.02
0.98
1.04
1.0
1.02
1.02
1.04
0.97
1.04
Day Median Price
13.45
5.86
4.3
41.85
104.8
5.66
14.1
293.2
1.75
8.35
Price Action Indicator
(0.15)
0.07
(0.05)
1.92
N/A
0.27
0.26
5.1
(0.04)
0.17
Coefficient Of Variation
746.37
9259.52
(2,535)
1120.55
642.84
(424.92)
1874.81
472.79
2005.46
1818.49
Mean Deviation
4.33
1.91
1.37
3.25
0.777
2.29
1.91
1.16
1.39
2.36
Jensen Alpha
0.9
0.015
(0.17)
0.2841
0.179
(0.75)
0.0974
0.2674
0.132
0.0744
Total Risk Alpha
0.2025
(0.22)
(0.43)
(0.05)
0.0574
(0.98)
(0.11)
0.1557
(0.11)
(0.15)
Sortino Ratio
0.1553
(0.02)
N/A
0.0648
0.0609
N/A
0.014
0.2005
0.0057
0.0267
Downside Variance
21.57
6.76
N/A
22.9
2.44
N/A
5.56
1.22
3.49
8.85
Standard Deviation
6.05
2.41
3.03
4.48
1.19
2.9
2.3
1.47
2.01
3.08
Kurtosis
1.38
0.4025
33.67
1.18
2.33
0.1626
(0.82)
(0.05)
2.71
0.7245
Potential Upside
14.77
3.44
2.29
8.76
2.12
3.9
3.53
3.18
3.05
5.45
Treynor Ratio
(0.64)
1.25
(0.27)
0.2941
(3.36)
(0.97)
0.5854
0.7111
(0.17)
0.1496
Maximum Drawdown
23.41
11.8
21.96
24.14
6.95
14.4
9.23
5.54
12.62
15.14
Variance
36.63
5.81
9.18
20.06
1.41
8.43
5.3
2.16
4.05
9.47
Market Risk Adjusted Performance
(0.63)
1.26
(0.26)
0.3041
(3.35)
(0.96)
0.5954
0.7211
(0.16)
0.1596
Risk Adjusted Performance
0.1166
0.0154
(0.02)
0.0801
0.1286
(0.18)
0.0495
0.1749
0.0462
0.0517
Skewness
1.19
0.0307
(4.61)
(0.24)
0.1459
0.0333
(0.05)
0.6556
0.2992
0.2742
Semi Deviation
3.71
2.39
N/A
4.2
0.8024
N/A
2.29
0.8004
1.61
2.6
Information Ratio
0.1192
(0.03)
(0.07)
0.0692
0.0801
(0.27)
0.0144
0.1505
0.0053
0.0259
Value At Risk
(7.19)
(3.93)
(2.27)
(5.60)
(1.53)
(5.63)
(3.36)
(1.57)
(2.79)
(4.49)
Expected Short fall
(6.08)
(1.99)
N/A
(3.27)
(1.21)
N/A
(1.93)
(1.41)
(1.93)
(2.95)
Downside Deviation
4.64
2.6
N/A
4.79
1.56
N/A
2.36
1.1
1.87
2.97
Semi Variance
13.75
5.71
N/A
17.63
0.6439
N/A
5.25
0.6407
2.6
6.76

Promis Neurosciences Competition Performance Charts

Five steps to successful analysis of Promis Neurosciences Competition

Promis Neurosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Promis Neurosciences in relation to its competition. Promis Neurosciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Promis Neurosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Promis Neurosciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Promis Neurosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Promis Neurosciences position

In addition to having Promis Neurosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Russia On Wall Street Thematic Idea Now

Russia On Wall Street
Russia On Wall Street Theme
Cross-sector and cross-instrument bundle of publicly traded Russian entities that are expected to be listed on USA exchanges or over the counter. The Russia On Wall Street theme has 23 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Russia On Wall Street Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Promis Neurosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Promis Neurosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Promis Neurosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Promis Neurosciences Stock:
How To Invest In Promis
Details
Is Promis Stock a good investment?
Details
What is Promis Neurosciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Promis Neurosciences Correlation with its peers.
For more detail on how to invest in Promis Stock please use our How to Invest in Promis Neurosciences guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Understanding that Promis Neurosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Promis Neurosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Promis Neurosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY